Rare diseases
Investigational molecules
Locations
Recruiting trials first
6 clinical trials in this condition
BelgiumBelgiumBelgiumBelgiumIn short
Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune condition that primarily affects the skin, causing distinctive rashes that appear mainly on sun-exposed areas of the body. While there is currently no permanent cure for this condition, a combination of treatment approaches can help control symptoms, reduce flare-ups, and improve quality of life for those living with SCLE.
When someone is diagnosed with subacute cutaneous lupus erythematosus, the main focus of treatment is to manage symptoms and prevent the condition from getting worse. The goals are quite practical: to improve the appearance and discomfort of skin lesions, to stop new rashes from developing, and to help patients maintain their daily activities without significant disruption.
Treatment approaches for SCLE depend heavily on how severe the condition is and how each individual responds to therapy. Some people may have mild rashes that only require topical treatments, while others develop more widespread skin involvement that needs stronger medications. The treatment plan also takes into account whether the person has systemic lupus erythematosus (SLE) alongside their skin symptoms, as about half of SCLE patients also have the more common systemic form of lupus.
There are established treatment methods that doctors have been using successfully for years, based on clinical guidelines and medical society recommendations. At the same time, researchers are actively investigating new therapies through clinical trials, seeking more effective ways to control this challenging condition. This means that patients today have access to proven treatments while also potentially benefiting from advances in medical research.
The foundation of treating subacute cutaneous lupus begins with protective measures that every patient needs to follow. Sun protection is absolutely essential because ultraviolet radiation is a major trigger for SCLE rashes. Healthcare providers strongly recommend that patients apply broad-spectrum sunscreen with a sun protection factor (SPF) of 50 or greater every single day, at least 20 minutes before going outside. This sunscreen needs to be reapplied every two to three hours for continued protection.
Beyond sunscreen, people with SCLE need to wear protective clothing such as wide-brimmed hats and long-sleeved shirts, and they should modify their behavior to avoid direct sun exposure whenever possible. A specific sunscreen containing ingredients called Mexoryl SX and Mexoryl XL was tested in a controlled trial and shown to prevent the development of ultraviolet-induced skin lesions in cutaneous lupus patients. Without adequate photoprotection, skin disease in SCLE is often very challenging to control, no matter what medications are used.
For local treatment of skin lesions, doctors typically prescribe topical corticosteroids (medications that reduce inflammation when applied directly to the skin). These come in different strengths, and healthcare providers usually recommend strong or very strong corticosteroid creams or ointments for SCLE rashes. They work by calming down the immune system's attack on skin cells, which helps reduce redness, scaling, and discomfort.
When topical treatments alone aren't enough, or when the rash is widespread, doctors turn to systemic medications (medicines taken by mouth or injection that work throughout the body). The standard first-line systemic therapy for SCLE consists of antimalarial drugs, particularly hydroxychloroquine or chloroquine. These medications were originally developed to treat malaria, but they have proven remarkably effective at controlling lupus symptoms. They work by reducing pain and inflammation, preventing flare-ups, and helping with lupus-related skin problems.
Hydroxychloroquine is usually the first antimalarial drug tried. If skin lesions don't respond adequately to hydroxychloroquine alone, doctors may add another antimalarial called quinacrine to improve the response. Some patients take these medications for extended periods—months or even years—to keep their condition under control. Regular monitoring is necessary because antimalarials can occasionally affect the eyes, so patients taking these drugs need periodic eye examinations.
For patients whose SCLE doesn't respond well to antimalarials, several other medication options exist. Methotrexate, an immunosuppressant drug, has been used to manage cutaneous lupus when other treatments fail. It works by dampening the overactive immune response. Dapsone, originally used to treat leprosy, has also shown effectiveness in SCLE treatment, particularly in cases with bullous (blistering) lesions. Case reports continue to support its use as an alternative therapy option.
Other medications that doctors sometimes prescribe for resistant SCLE include retinoids (vitamin A derivatives), thalidomide or lenalidomide (immunomodulatory drugs), and gold compounds, though these are used less frequently due to their side effect profiles. Each medication carries its own potential side effects, ranging from mild gastrointestinal upset to more serious complications, so treatment decisions involve carefully weighing benefits against risks for each individual patient.
The duration of treatment varies greatly from person to person. Some patients may achieve remission (a period when symptoms disappear) and can gradually reduce their medications, while others need ongoing therapy to keep symptoms controlled. Healthcare providers typically adjust treatment intensity based on disease activity, meaning they may increase medications during flare-ups and reduce them when the condition is stable.
While standard treatments help many people with SCLE, researchers recognize that some patients don't respond adequately to conventional therapies. This has spurred significant research into new treatment approaches, with several promising therapies now being evaluated in clinical trials.
One of the most encouraging areas of research focuses on targeting type I interferons, proteins that play a central role in SCLE development. Scientists have discovered that people with cutaneous lupus have elevated levels of genes regulated by type I interferons in their blood, and these levels correlate with how severe their skin disease is. This discovery has made interferon pathways an attractive target for new medications.
Anifrolumab is a monoclonal antibody (a laboratory-made protein that mimics the immune system's ability to fight harmful substances) that blocks the type I interferon receptor. By blocking this receptor, anifrolumab prevents interferons from triggering the inflammatory cascade that damages skin. The significant role of type I interferons in SCLE, combined with encouraging clinical data, suggests anifrolumab as a very promising agent for treating cutaneous lupus. Clinical trials have been investigating its effectiveness specifically for lupus patients with active skin disease.
Another investigational drug is BIIB059, which targets a specific component of the immune system involved in SCLE. Early data from clinical trials has been supportive, showing this drug as a promising new strategy for treating cutaneous lupus. The medication works by interfering with particular immune pathways that contribute to skin inflammation.
Two biologic medications already approved for systemic lupus erythematosus have also shown promise for treating severe SCLE. Rituximab is a monoclonal antibody that targets B cells (a type of white blood cell that produces antibodies). By depleting B cells, rituximab can reduce the autoimmune attack on skin tissue. Studies have demonstrated efficacy in patients with SLE who also have severe active cutaneous lupus. Similarly, belimumab, which blocks a protein called B-lymphocyte stimulator (BLyS) that helps B cells survive, has shown effectiveness in patients with systemic lupus who have significant skin involvement.
Ustekinumab, a medication already approved for treating psoriasis and other inflammatory conditions, is being explored as a potential treatment for SCLE. This drug blocks two inflammatory proteins called interleukin-12 and interleukin-23, which contribute to immune system dysfunction in autoimmune diseases. Early evidence supports its potential usefulness in cutaneous lupus.
Dapirolizumab is another investigational antibody being tested in lupus patients. While research is still in earlier phases, preliminary data suggests it may offer benefits for those with active disease, including skin manifestations.
A newer class of medications called JAK inhibitors (Janus kinase inhibitors) is also being investigated for SCLE. These drugs block enzymes involved in the signaling pathways that trigger inflammation. Several different JAK inhibitors have shown promise in early studies of lupus patients, and researchers are continuing to evaluate their effectiveness and safety specifically for cutaneous manifestations.
Clinical trials for SCLE treatments are being conducted in various locations worldwide, including in the United States, Europe, and other regions. Eligibility for these trials typically depends on several factors: the severity of your skin disease, whether you have tried and failed standard treatments, whether you have systemic lupus alongside your skin symptoms, and various other health considerations. Each trial has specific inclusion and exclusion criteria that determine who can participate.
One intriguing finding from recent research is that patients with a more TLR9-driven disease pathology (meaning their condition is driven by a particular immune receptor called Toll-like receptor 9) may benefit more from hydroxychloroquine treatment. This discovery suggests that in the future, doctors might be able to use biomarkers (measurable indicators of disease processes) to predict which patients will respond best to which treatments, allowing for more personalized medicine approaches.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
